Breast cancer-related lymphedema: A comprehensive analysis of risk factors.
breast cancer lymphedema
lymph node excision
mastectomy
risk factors
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
revised:
11
07
2024
received:
04
06
2024
accepted:
11
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Breast cancer-related lymphedema is a devastating condition that negatively affects the quality of life of breast cancer survivors. We sought to identify risk factors that predicted the timing and development of lymphedema. Women with breast cancer that underwent sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) at our institution between 2007 and 2022 were identified and sociodemographic and clinical information was extracted. We used logistic regression analysis to identify risk factors for lymphedema and performed cox-regression analysis to predict the timing of lymphedema presentation after surgery. We identified 1,223 patients, of which 161 (13.2%) developed lymphedema within 1.8 (mean, SD = 2.5) years postoperatively. Patients with SLNB had significantly lower odds for lymphedema development (vs. ALND, OR = 0.29 [0.14-0.57]). Patients between 40 and 49 years of age, and 50-59 (vs. <40 years, OR = 2.14 [1.00-4.60]; OR = 2.42, [1.13-5.16] respectively), African American patients (vs. Caucasian, OR = 1.86 [1.12-3.09]), patients with stage II, III, and IV disease (vs. stage 0, OR = 3.75 [1.36-10.33]; OR = 6.62 [2.14-20.51]; OR = 9.36 [2.94-29.81]), and patients with Medicaid (vs. private insurance, OR = 3.56 [1.73-7.28]) had higher rates of lymphedema. Cox-regression analysis showed that African American (HR = 1.71 [1.08-2.70]), higher BMI (HR = 1.03 [1.00-1.06]), higher stage (stage II, HR = 2.22 [1.05-7.09]; stage III, HR = 5.26 [1.86-14.88]; stage IV, HR = 6.13 [2.12-17.75]), and Medicaid patients (HR = 2.15 [1.12-3.80]) had higher hazards for lymphedema. Patients with SLNB had lower hazards for lymphedema (HR = 0.43 [0.87-2.11]). Lymphedema has identifiable risk factors that can reliably be used to predict the chances of lymphedema development and enable clinicians to educate patients better and formulate treatment plans accordingly. III (Retrospective study).
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer-related lymphedema is a devastating condition that negatively affects the quality of life of breast cancer survivors. We sought to identify risk factors that predicted the timing and development of lymphedema.
METHODS
METHODS
Women with breast cancer that underwent sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) at our institution between 2007 and 2022 were identified and sociodemographic and clinical information was extracted. We used logistic regression analysis to identify risk factors for lymphedema and performed cox-regression analysis to predict the timing of lymphedema presentation after surgery.
RESULTS
RESULTS
We identified 1,223 patients, of which 161 (13.2%) developed lymphedema within 1.8 (mean, SD = 2.5) years postoperatively. Patients with SLNB had significantly lower odds for lymphedema development (vs. ALND, OR = 0.29 [0.14-0.57]). Patients between 40 and 49 years of age, and 50-59 (vs. <40 years, OR = 2.14 [1.00-4.60]; OR = 2.42, [1.13-5.16] respectively), African American patients (vs. Caucasian, OR = 1.86 [1.12-3.09]), patients with stage II, III, and IV disease (vs. stage 0, OR = 3.75 [1.36-10.33]; OR = 6.62 [2.14-20.51]; OR = 9.36 [2.94-29.81]), and patients with Medicaid (vs. private insurance, OR = 3.56 [1.73-7.28]) had higher rates of lymphedema. Cox-regression analysis showed that African American (HR = 1.71 [1.08-2.70]), higher BMI (HR = 1.03 [1.00-1.06]), higher stage (stage II, HR = 2.22 [1.05-7.09]; stage III, HR = 5.26 [1.86-14.88]; stage IV, HR = 6.13 [2.12-17.75]), and Medicaid patients (HR = 2.15 [1.12-3.80]) had higher hazards for lymphedema. Patients with SLNB had lower hazards for lymphedema (HR = 0.43 [0.87-2.11]).
CONCLUSION
CONCLUSIONS
Lymphedema has identifiable risk factors that can reliably be used to predict the chances of lymphedema development and enable clinicians to educate patients better and formulate treatment plans accordingly.
LEVEL OF EVIDENCE
METHODS
III (Retrospective study).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta‐analysis. Lancet Oncol. 2013;14(6):500‐515. doi:10.1016/s1470-2045(13)70076-7
Hespe GE, Nores GG, Huang JJ, Mehrara BJ. Pathophysiology of lymphedema‐is there a chance for medication treatment? J Surg Oncol. 2017;115(1):96‐98. doi:10.1002/jso.24414
Chachaj A, Małyszczak K, Pyszel K, et al. Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. Psycho‐Oncol. 2010;19(3):299‐305. doi:10.1002/pon.1573
Taghian NR, Miller CL, Jammallo LS, O'Toole J, Skolny MN. Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol. 2014;92(3):227‐234. doi:10.1016/j.critrevonc.2014.06.004
Fish ML, Grover R, Schwarz GS. Quality‐of‐life outcomes in surgical vs nonsurgical treatment of breast cancer‐related lymphedema: a systematic review. JAMA Surg. 2020;155(6):513‐519. doi:10.1001/jamasurg.2020.0230
Rockson SG. Advances in lymphedema. Circ Res. 2021;128(12):2003‐2016. doi:10.1161/circresaha.121.318307
Siotos C, Hassanein AH, Bello RJ, et al. Delayed breast reconstruction on patients with upper extremity lymphedema: a systematic review of the literature and pooled analysis. Ann Plast Surg. 2018;81(6):730‐735. doi:10.1097/sap.0000000000001542
Belmonte R, Messaggi‐Sartor M, Ferrer M, Pont A, Escalada F. Prospective study of shoulder strength, shoulder range of motion, and lymphedema in breast cancer patients from pre‐surgery to 5 years after ALND or SLNB. Supp Care Cancer. 2018;26(9):3277‐3287. doi:10.1007/s00520-018-4186-1
Che Bakri NA, Kwasnicki RM, Khan N, et al. Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients: a systematic review and meta‐analysis. Ann Surg. 2023;277(4):572‐580. doi:10.1097/sla.0000000000005671
Teshome MBK, McCall LM, Cormier JN, Guiliano AE, Hunt KK. Long‐term incidence of lymphedema after sentinel lymph node dissection for early stage breast cancer: ACOSOG Z0010 (Alliance) Presented at: 67th Annual Cancer Symposium Society of Surgical Oncology. 2014
Murphy CD, Schulick RD. Racial disparities in breast cancer: more bad news. JAMA Surg. 2014;149(8):796‐797. doi:10.1001/jamasurg.2014.44
Rochlin DH, Barrio AV, McLaughlin S, et al. Feasibility and clinical utility of prediction models for breast cancer‐related lymphedema incorporating racial differences in disease incidence. JAMA Surg. 2023;158(9):954‐964. doi:10.1001/jamasurg.2023.2414
Kwan ML, Yao S, Lee VS, et al. Race/ethnicity, genetic ancestry, and breast cancer‐related lymphedema in the Pathways Study. Breast Cancer Res Treat. 2016;159(1):119‐129. doi:10.1007/s10549-016-3913-x
Morehead‐Gee AJ, Pfalzer L, Levy E, et al. Racial disparities in physical and functional domains in women with breast cancer. Supp Care Cancer. 2012;20(8):1839‐1847. doi:10.1007/s00520-011-1285-7
Norman SA, Localio AR, Kallan MJ, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prevent. 2010;19(11):2734‐2746. doi:10.1158/1055-9965.Epi-09-1245
Clough‐Gorr KM, Ganz PA, Silliman RA. Older breast cancer survivors: factors associated with self‐reported symptoms of persistent lymphedema over 7 years of follow‐up. Breast J. 2010;16(2):147‐155. doi:10.1111/j.1524-4741.2009.00878.x
Shih YCT, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2‐year follow‐up study. J Clin Oncol. 2009;27(12):2007‐2014. doi:10.1200/jco.2008.18.3517
Mesquita‐Neto JWB, Cmorej P, Mouzaihem H, Weaver D, Kim S, Macedo FI. Disparities in access to cancer surgery after Medicaid expansion. Am J Surg. 2020;219(1):181‐184. doi:10.1016/j.amjsurg.2019.06.023
Jiang HJ, Weiss AJ, Barrett ML, Sheng M. Characteristics of hospital stays for Super‐Utilizers by Payer, 2012 Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality (US). 2006.
Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early‐stage breast cancer. N Engl J Med. 2015;373(4):307‐316. doi:10.1056/NEJMoa1415340
Warren LEG, Miller CL, Horick N, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88(3):565‐571. doi:10.1016/j.ijrobp.2013.11.232
Johnson AR, Kimball S, Epstein S, et al. Lymphedema incidence after axillary lymph node dissection: quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Ann Plast Surg. 2019;82(4S suppl 3):S234‐S241. doi:10.1097/sap.0000000000001864
Chang DW, Kim S. Breast reconstruction and lymphedema. Plast Reconstr Surg. 2010;125(1):19‐23. doi:10.1097/PRS.0b013e3181c49477
Siotos C, Sebai ME, Wan EL, et al. Breast reconstruction and risk of arm lymphedema development: a meta‐analysis. J Plastic Reconstruct Aesth Surg. 2018;71(6):807‐818. doi:10.1016/j.bjps.2018.01.012
Miller CL, Colwell AS, Horick N, et al. Immediate implant reconstruction is associated with a reduced risk of lymphedema compared to mastectomy alone: a prospective cohort study. Ann Surg. 2016;263(2):399‐405. doi:10.1097/sla.0000000000001128
Lee KT, Bang SI, Pyon JK, Hwang JH, Mun GH. Method of breast reconstruction and the development of lymphoedema. Br J Surg. 2017;104(3):230‐237. doi:10.1002/bjs.10397
Crosby MA, Card A, Liu J, Lindstrom WA, Chang DW. Immediate breast reconstruction and lymphedema incidence. Plast Reconstr Surg. 2012;129(5):789e‐795e. doi:10.1097/PRS.0b013e31824a2ab1
Slavin SA, Upton J, Kaplan WD, Van den Abbeele AD. An investigation of lymphatic function following free‐tissue transfer. Plast Reconstr Surg. 1997;99(3):730‐741. doi:10.1097/00006534-199703000-00020